RTP Mobile Logo
BCU319

Interview with Matthew Goetz, MD

Track 1: Case: A woman in her mid-30s with de novo ER-positive, HER2-negative metastatic breast cancer (mBC) achieves a complete clinical response to palbociclib, letrozole and ovarian suppression
Track 2: Importance of providing support to patients and their families coping with a diagnosis of mBC
Track 3: Therapeutic options for patients with de novo ER-positive, HER2-negative mBC
Track 4: Activity and tolerability of gonadotropin-releasing hormone agonists
Track 5: Selection of patients for treatment with CDK4/6 inhibitors in combination with endocrine therapy
Track 6: Mechanism of action of CDK4/6 inhibitors
Track 7: Role of everolimus and alpelisib in the management of ER-positive mBC
Track 8: Implications of ESR1 mutations for the management of ER-positive mBC; use of selective estrogen receptor degraders (SERDs)
Track 9: Activity of the selective estrogen receptor modulators endoxifen and lasofoxifene for mBC with ESR1 mutation
Track 10: Tolerability profiles of the CDK4/6 inhibitors palbociclib, ribociclib and abemaciclib; dose reduction to mitigate side effects
Track 11: CNS penetration of abemaciclib; management of abemaciclib-associated diarrhea
Track 12: Effects of site and extent of metastases on outcomes with CDK4/6 inhibitors
Track 13: Efficacy of CDK4/6 inhibitors in combination with endocrine therapy for ER-positive mBC
Track 14: Survival outcomes with CDK4/6 inhibitors and endocrine therapy for ER-positive mBC
Track 15: Response to palbociclib and endocrine therapy in patients with ER-positive mBC
Track 16: Selection of therapy for patients with locally advanced ER-positive, HER2-negative breast cancer
Track 17: Therapeutic approach for patients who experience disease progression on a CDK4/6 inhibitor
Track 18: Activity of alpelisib for ER-positive advanced breast cancer with a PIK3CA mutation
Track 19: Side-effect profile of alpelisib
Track 20: Case: A woman in her late 60s with high-grade, ER-positive, HER2-negative breast cancer and a 21-gene assay Recurrence Score (RS) of 52 receives adjuvant chemotherapy
Track 21: Role of bone-modifying agents for patients with ER-positive breast cancer and bone metastases
Track 22: Ongoing investigations of CDK4/6 inhibitors in the adjuvant setting
Track 23: Effects of CDK4/6 inhibitors on immunity; potential for combination with immune checkpoint inhibitors
Track 24: TAILORx trial: Adjuvant chemotherapy guided by a 21-gene expression assay for women with ER-positive, HER2-negative, node-negative breast cancer
Track 25: Impact of clinical risk on prognosis and prediction of chemotherapy benefit by age and RS in the TAILORx study for patients with early breast cancer
Track 26: Perspective on the use of gene expression assays to determine risk of recurrence and guide adjuvant decision-making
Track 27: Cancer cell dormancy and risk of late recurrence

Interview with Virginia Kaklamani, MD, DSc

Track 1: Efficacy and safety of the novel SERD elacestrant for ER-positive breast cancer; Phase III EMERALD trial evaluating elacestrant versus endocrine therapy
Track 2: Incidence of ESR1 mutations; activity of elacestrant after disease progression on fulvestrant and a CDK4/6 inhibitor
Track 3: Results from the Phase II ANETT trial of the mTORC1/2 inhibitor TAK-228 with tamoxifen as neoadjuvant therapy for ER-positive breast cancer
Track 4: Novel approaches under investigation in the neoadjuvant setting
Track 5: Perspective on the use of neoadjuvant therapy to optimize surgical outcomes for patients with ER-positive, HER2-negative breast cancer
Track 6: Activity of CDK4/6 inhibitors for locally advanced ER-positive breast cancer
Track 7: Case: A woman in her late 60s with ER-positive, HER2-negative breast cancer and 1 of 3 positive axillary lymph nodes receives a 21-gene assay RS of 18
Track 8: Role of the 21-gene expression assay in predicting chemotherapy benefit for patients with ER-positive breast cancer
Track 9: Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer
Track 10: Case: A premenopausal woman in her late 40s with ER-positive, HER2-negative, node-negative breast cancer receives a RS of 19
Track 11: Clinical implications of the TAILORx trial comparing chemoendocrine therapy to endocrine therapy for patients with ER-positive, node-negative breast cancer and an intermediate RS
Track 12: Tailoring adjuvant endocrine therapy for premenopausal women with ER-positive breast cancer
Track 13: Benefit of endocrine therapy with or without chemotherapy for patients with ER-positive breast cancer and an intermediate RS; consideration of clinical and genomic risk in assessing the likelihood of disease recurrence
Track 14: Case: A woman in her early 40s with ER-positive, HER2-negative breast cancer and metastases in the liver and bones attains a partial response to ribociclib in combination with endocrine therapy
Track 15: Benefit with CDK4/6 inhibitors versus chemotherapy for ER-positive breast cancer with visceral metastases
Track 16: Efficacy of ribociclib in premenopausal women; QT prolongation associated with ribociclib/tamoxifen
Track 17: Comparison of the efficacy and toxicity profiles of abemaciclib, palbociclib and ribociclib for women with ER-positive mBC
Track 18: Activity of CDK4/6 inhibitors as monotherapy; CNS penetration of CDK4/6 inhibitors
Track 19: Monitoring and management of side effects associated with CDK4/6 inhibitors
Track 20: Case: A woman in her mid-50s initially diagnosed with Stage II ER-positive breast cancer develops metastatic disease to the bone 8 years later and receives palbociclib and anastrozole
Track 21: Perspective on the use of multiplex genomic assays to guide treatment decision-making for patients with ER-positive mBC
Track 22: Results of the Phase III SOLAR-1 trial evaluating alpelisib for patients with ER-positive advanced breast cancer
Track 23: Tolerability of alpelisib for patients with ER-positive breast cancer
Track 24: Sequencing everolimus and alpelisib after disease progression on a CDK4/6 inhibitor
Track 25: Case: A postmenopausal woman in her mid-30s with ER-positive mBC and BRCA2 and PIK3CA mutations receives talazoparib in the third-line setting
Track 26: Choice of PARP inhibitor for patients with advanced breast cancer and BRCA mutations
Track 27: Response and side-effect profiles of alpelisib
Track 28: Selection and sequencing of therapy for patients with mBC and germline BRCA mutations
 
FACULTY
 
Matthew Goetz, MD
Professor of Oncology and Pharmacology
Mayo Clinic
Rochester, Minnesota
 
Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers
Chair in Breast Cancer
Research and Treatment
AB Alexander Distinguished
Chair in Oncology
Associate Director for
Clinical Research
Leader of the Breast Cancer Program
UT Health San Antonio
The University of Texas
MD Anderson Cancer Center
San Antonio, Texas
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida